Tag Archives: Evan Seigerman

Satsuma Pharmaceuticals (STSA) Gets a Buy Rating from Credit Suisse

Credit Suisse analyst Evan Seigerman maintained a Buy rating on Satsuma Pharmaceuticals (STSA – Research Report) yesterday and set a price target of $33.00. The company’s shares closed last Friday at $23.02. According to TipRanks.com, Seigerman is a 5-star analyst

Galera Therapeutics (GRTX) Gets a Hold Rating from Credit Suisse

In a report released today, Evan Seigerman from Credit Suisse maintained a Hold rating on Galera Therapeutics (GRTX – Research Report), with a price target of $8.00. The company’s shares closed last Wednesday at $7.66, close to its 52-week low

Credit Suisse Sticks to Its Hold Rating for Aimmune Therapeutics (AIMT)

Credit Suisse analyst Evan Seigerman maintained a Hold rating on Aimmune Therapeutics (AIMT – Research Report) today and set a price target of $15.00. The company’s shares closed last Wednesday at $13.83, close to its 52-week low of $10.09. According

Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Amedisys (AMED)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGN – Research Report) and Amedisys (AMED – Research Report) with bullish sentiments. Amgen (AMGN) In a report released yesterday, Evan

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (NASDAQ: BIIB) and uniQure (NASDAQ: QURE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB – Research Report) and uniQure (QURE – Research Report). Biogen (BIIB) Credit Suisse analyst Evan Seigerman maintained a Hold rating on

Satsuma Pharmaceuticals (STSA) Receives a Buy from Credit Suisse

In a report released yesterday, Evan Seigerman from Credit Suisse maintained a Buy rating on Satsuma Pharmaceuticals (STSA – Research Report), with a price target of $32.00. The company’s shares closed last Wednesday at $20.28. According to TipRanks.com, Seigerman is